Biostratum
BioStratum Inc. globally offers basal lamina research services for treating kidney disease, cancer, and autoimmune diseases.
Founded
1994BioStratum Inc. globally offers basal lamina research services for treating kidney disease, cancer, and autoimmune diseases.
Founded with a mission to advance medical research and therapeutic solutions, BioStratum Inc. specializes in developing therapeutic agents targeting basal lamina for the treatment of kidney disease, cancer, and autoimmune diseases. The company offers comprehensive research services aimed at understanding and manipulating basal lamina structures to create effective treatments. BioStratum serves a global market, focusing on providing innovative healthcare solutions that address some of the most challenging medical conditions.
BioStratum has garnered attention for its pioneering work in basal lamina research, attracting notable scientists and investors in the biomedical field. The company's key achievements include significant advancements in therapeutic approaches for kidney disease and cancer, contributing to the broader medical community's understanding of these diseases. Through its impactful research and development efforts, BioStratum has established itself as a crucial player in the biotechnology sector, driving progress in medical treatments and improving patient outcomes worldwide.
Companies similar to Biostratum include BioSurfaces, Antria, Know Bio and Strykagen.
Biostratum was founded in 1994.
Biostratum's headquarters is located in Durham, NC, US.
Biostratum's most recent funding round was for $600k (USD) in August 2011.
As of Aug 19, 2011, Biostratum has disclosed funding of $10.1M (USD). Undisclosed round amounts are excluded.
Biostratum has 7 employees as of Feb 5, 2024.
Strykagen
strykagen.com
